Meeting report : Neuropathology and Neuropharmacology of Monoaminergic systems [PDF]
, 2014 The third EU COST Action CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain” Annual Conference entitled “Neuropathology and ...
De Deurwaerdere, Philippe +1 more
core +1 more source
The MAO Inhibitor Tranylcypromine Alters LPS- and A beta-Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD [PDF]
, 2020 Monoamine oxidase (MAO) has been implicated in neuroinflammation, and therapies targeting MAO are of interest for neurodegenerative diseases. The small-molecule drug tranylcypromine, an inhibitor of MAO, is currently used as an antidepressant and in the ...
Han, Kyung-Min +11 more
core +1 more source
NF-Y substitutes H2A-H2B on active cell-cycle promoters: recruitment of CoREST-KDM1 and fine-tuning of H3 methylations [PDF]
, 2008 The CCAAT box is a frequent promoter element, as illustrated by bioinformatic analysis, and it is bound by NF-Y, a trimer with H2A-H2B-like subunits. We developed a MNase I-based ChIP protocol on homogeneous cell populations to study cell-cycle promoters
Adkins +84 more
core +2 more sources
A BRAZILIAN CASE OF TREATMENT-RESISTANT GENERALIZED ANXIETY DISORDER SUCCESSFULLY TREATED WITH MONOAMINE OXIDASE INHIBITOR (MAOI) [PDF]
, 2020 In this brief report we present the case of a 53 year old man with a very debilitating Generalized Anxiety Disorder successfully treated with tranylcypromine. After several failed treatment attempts following international guidelines recommendations over
Azevedo Quagliato, Laiana +6 more
core +1 more source
Combination Therapy with Monoamine Oxidase Inhibitors and Other Antidepressants or Stimulants: Strategies for the Management of Treatment‐Resistant Depression [PDF]
, 2015 Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/111275/1/phar1576 ...
Bostwick, Jolene R. +3 more
core +1 more source
Etiology and Management of Sexual Dysfunction [PDF]
, 2009 Sexual dysfunction is the impairment or disruption of any of the three phases of normal sexual functioning, including loss of libido, impairment of physiological arousal and loss, delay or alteration of orgasm.
Bevinahalli Nanjegowda, Raveesh +5 more
core +2 more sources
MAO-inhibitors in Parkinson's Disease [PDF]
, 2011 Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson's disease (PD). They have been used with or without levodopa (L-DOPA).
Ahlskog +162 more
core +2 more sources
Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class [PDF]
, 2016 New psychoactive substances (NPS) are not tested for their cytochrome P450 (CYP) inhibition potential before consumption. Therefore, this potential was explored for tryptamine-derived NPS (TDNPS) including alpha-methyl tryptamines (AMTs), dimethyl ...
Brandt, SD +4 more
core +1 more source
Brain and Behavior, Volume 15, Issue 2, February 2025.Hospitalized patients often experience sleep disturbances due to various factors, leading to negative health outcomes. A multi‐faceted approach, including environmental modifications, pharmacological interventions, and non‐pharmacological strategies, can significantly improve sleep quality and patient outcomes.
Ghazal Roostaei +7 more
wiley +1 more source
What's best when a patient doesn't respond to the maximum dose of an antidepressant? [PDF]
, 2010 Consider possible causes of the inadequate response, then weigh treatment options in light of the characteristics of the individual patient and therapy. When managing a patient with nonpsychotic depression and inadequate response to the maximum dose of a
Lo, Vincent, Maggio, Lauren
core